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Abstract
Background: Giant axonal neuropathy (GAN) is a hereditary neurological disorder that affects
both central and peripheral nerves. The main pathological hallmark of the disease is abnormal
accumulations of intermediate filaments (IFs) in giant axons and other cell types. Mutations in the
GAN gene, encoding gigaxonin, cause the disease. Gigaxonin is important in controlling protein
degradation via the ubiquitin-proteasome system. The goal of this study was to examine global
alterations in gene expression in fibroblasts derived from newly identified GAN families compared
with normal cells.
Results: We report the characterization of fibroblast explants obtained from two unrelated GAN
patients. We identify three novel putative mutant GAN alleles and show aggregation of vimentin IFs
in these fibroblasts. By microarray analysis, we also demonstrate that the expression of lipid
metabolism genes of the GAN fibroblasts is disrupted, which may account for the abnormal
accumulations of lipid droplets in these cells.
Conclusion: Our findings suggest that aberrant lipid metabolism in GAN patients may contribute
to the progression of the disease.
Background
Giant Axonal Neuropathy (GAN) is a severe autosomal
recessive disorder that affects both the central and periph-
eral nervous systems. The most prominent pathological
feature of GAN is the large, focal accumulations of neuro-
nal intermediate filaments (IFs) in distended axons [1].
Abnormal aggregations of IFs have also been found in
astrocytes, endothelial cells, Schwann cells and cultured
skin fibroblasts. Many GAN patients have frizzy hair that
is distinctive from their parents. Chemical analysis of the
hair has revealed a disruption of disulfide-bond forma-
tion in hair keratins [2]. Hence, a generalized disorganiza-
tion of IFs has been proposed to be responsible for GAN
[3].
Skin fibroblast explants collected from GAN patients have
been used as a model to study the disease. Under normal
culture conditions, a low percentage of GAN fibroblasts
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exhibit abnormal aggregation and bundling of vimentin
IFs [4-7]. Upon various stimuli, such as low serum [5] or
low doses of trypsin [6], the vimentin networks of GAN
fibroblasts collapse and form aggregates. Moreover, the
microtubule (MT)-depolymerizing agent nocodazole
exerts different effects on normal and GAN fibroblasts.
Although the IF networks of both types of fibroblasts col-
lapse under nocodazole treatment, the aggregates formed
in GAN cells are significantly more compact and dense
[5]. Together, these data suggest that dysfunction of the
GAN gene product might cause IFs to form aggregates that
are harmful to cells.
A GAN gene has been identified and its product named
gigaxonin, with twenty-three different mutations reported
to date [8-10]. Gigaxonin is a member of the kelch repeat
superfamily. It contains an N-terminal BTB/POZ (Broad-
Complex, Tramtrack and Bric-a-brac/Poxvirus and Zinc-
finger) domain and six C-terminal kelch motifs. MT-Asso-
ciated Protein 1B (MAP1B), Tubulin Cofactor B (TBCB),
and MT-Associated Protein 8 (MAP8 or MAP1S) have
been identified as binding partners of gigaxonin in yeast
two-hybrid screens [11-14]. Gigaxonin interacted with
these proteins via the kelch repeats. The N-terminal BTB of
gigaxonin could bind ubiquitin-activating enzyme E1,
suggesting that gigaxonin functions as a scaffold protein
in the ubiquitin-proteasome complex and mediates the
degradation of MAP1B, TBCB and MAP8 [11]. Mutations
in the GAN gene result in accumulation of these cytoskel-
etal proteins and eventual neurodegeneration.
Here, we report the characterization of two primary lines
of cultured GAN fibroblasts carrying a total of three puta-
tive disease-linked GAN alleles. We compared the gene
expression profiles of the GAN fibroblasts to those of nor-
mal fibroblasts. We found that the expression of lipid
metabolism genes was perturbed in GAN fibroblasts most
dramatically. In addition to changes in the expression lev-
els of lipid metabolism genes, we also discovered an
increase in the number of neutral lipid droplets in GAN
cells. These data suggest that defects in lipid metabolism
may contribute to the pathogenesis of GAN.
Results
Genotyping of fibroblast explants
Four subcutaneous fibroblasts explants, MCH068,
MCH070, WG0321 and WG0791, were obtained from the
repository for mutant human cell strains at the McGill
University Health Center. MCH068 and MCH070 cells
were isolated from normal individuals while WG0321
and WG0791 cells were isolated from patients diagnosed
with GAN. Both GAN patients experienced difficulty in
walking and their electromyography showed diffuse
axonal neuropathy. We sequenced the GAN cDNAs pre-
pared from the fibroblast explants. No mutations were
detected in MCH068 and MCH070 cells. We obtained
two PCR products from WG0791 cells, a major product of
~1.8 kb and a minor product of ~1.7 kb (data not shown).
Sequencing of the 1.8-kb product revealed that a missense
mutation in exon 3 (c.545T>A). The mutation resulted in
the substitution of the isoleucine at amino acid position
182 with an asparagine, I182N (Fig. 1A). The 1.7-kb frag-
ment represented an mRNA product from the other GAN
allele because it did not contain the I182N mutation. It
was shorter than the wild-type message because it did not
contain exon 2 (Fig. 1B). We then sequenced the first three
exons and the intron-exon junctions of the GAN  gene
from WG0791 cells. While confirming the I182N mis-
sense mutation, we also discovered an A→C mutation
near the exon 2-intron 2 junction (c.282+3A>C), which
might account for the misspliced message (data not
shown).
Sequencing of the GAN cDNA prepared from WG0321
cells revealed a deletion/insertion in the GAN message:
nucleotides 1505–2056 were replaced with a 452-nucle-
otide-long sequence that was identical to a part of intron
9 of the GAN gene (Fig. 1C). We sequenced the 3' region
of the GAN gene from WG0321 cells and discovered that
the entire exon 10 and 446 base pairs of the exon 11 5'end
were deleted in both alleles. The deletion caused exon 9 to
be spliced into intron 9 (data not shown). A schematic
representation of the mutated and normal GAN alleles is
shown in Fig. 1D.
Because we were unable to screen additional healthy con-
trols, the three novel GAN alleles should be considered
putative disease-associated mutations.
Characterization of GAN fibroblasts
Previous studies have shown that vimentin IFs form
abnormal aggregates in GAN fibroblasts and that low-
serum treatment enhances the aggregation. To determine
whether WG0321 and WG0791 cells also contained IF
aggregates, we performed immunocytochemical staining
with antibodies against various IF proteins. In complete
medium, 12% of WG0791 cells and 23% of WG0321 cells
displayed compact vimentin aggregates. Upon low-serum
treatment for 72 hours, the number of cells containing
vimentin aggregates dramatically increased, up to 50% for
WG0791 cells and 95% for WG0321 cells (Fig. 2A).
Vimentin aggregates were never detected in normal
fibroblasts, MCH068 and MCH070. Interestingly,
although cytokeratins are usually not expressed in fibrob-
lasts, a small percentage of both normal and GAN cells
(~2%) exhibited positive staining for keratins (Fig. 2B–E).
In GAN cells, some of the IF aggregates contained both
vimentin and cytokeratin (Fig. 2D and 2E).BMC Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2156/8/6
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GAN mutations in GAN fibroblasts Figure 1
GAN mutations in GAN fibroblasts. (A) Sequencing of the 1.8-kb RT-PCR product from MCH070 (wild-type) and WG0791 
(GAN) cells. The WG0791 product contains an A→T missense mutation. The affected codon is underlined. (B) Sequencing of 
the 1.7-kb RT-PCR product from WG0791 (GAN) and the 1.8-kb product from MCH070 (wild-type) cells. GAN exon 2 is 
skipped in the 1.7-kb WG0791 product, resulting in an out-of-frame premature stop codon (*). (C) Sequencing of the RT-PCR 
products from MCH070 (wild-type) and WG0321 (GAN) cells. The WG0321 product includes part of intron 9. (D) Schematic 
representation of the GAN mutations in WG0321 and WG0791 patients. Because of a 9.3-kb deletion in the WG0321 allele, a 
portion of intron 9 is included in the mRNA (gray box). The intronic mutation in WG0791 is indicated with an arrowhead. The 
positions of the RT-PCR primers used to amplify GAN cDNA are also shown (arrows).
(a)
(b)
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Cytological analysis of normal and GAN fibroblasts Figure 2
Cytological analysis of normal and GAN fibroblasts. (A) Fractions of wild-type and GAN cells containing vimentin aggregates in 
normal and low-serum media. Upon low-serum treatment, there was a dramatic increase of vimentin aggregates in GAN cells, 
from 12% to 43% for WG0791 cells and from 19% to 89% for WG0321 cells. Vimentin did not form aggregates in normal cells 
under any culture conditions. (B and C) Immunostaining of MCH070 (wild-type) cells with a polyclonal anti-vimentin antibody 
(B) and a monoclonal anti-pan-keratin antibody (C). A small percentage of MCH070 fibroblasts expressed both vimentin and 
keratins. Both of these intermediate filament proteins could form an extensive filament network. (D and E) Immunostaining of 
WG0321 (GAN) cells with a polyclonal anti-vimentin antibody (D) and a monoclonal anti-pan-keratin antibody (E). Similar to 
MCH070, a small percentage of WG0321 fibroblasts expressed vimentin and keratins. Both proteins could be found in the 
aggregates (white arrows). Note that some vimentin aggregates did not contain keratins (arrowheads in D). Scale bar, 10 μm.
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Microarray analysis of GAN fibroblasts
We studied the expression profiles of GAN and normal
fibroblasts grown in low-serum medium by microarray
(Affymetrix) analysis. To reduce the background noise, we
performed a four-way comparison of MCH068, MCH070,
WG0321 and WG0791 cells. We selected genes that
showed consistent changes in WG0321 and WG0791
fibroblasts when compared to MCH068 and MCH070
cells. Genes that exhibited more than three-fold differ-
ences are grouped in Table 1 in the Supplemental Data
according to their proposed functions. Gene products
involved in lipid metabolism displayed the most dramatic
changes. We confirmed the relative expression levels of
these lipid metabolism genes by quantitative RT-PCR (Fig.
3). The results were in agreement with the microarray
experiments. We also performed quantitative RT-PCR to
determine the expression levels of gigaxonin in GAN
fibroblasts (Fig. 3A). Compared to MCH068 and
MCH070,  GAN  mRNA expression was dramatically
upregulated in WG0321 (~26 fold) and WG0791 (~7
fold) cells.
We also detected significant changes in members of the
ATP-Binding Cassette (ABC) protein family, ABCA6 and
ABCB4. ABC transporters are multispan transmembrane
proteins that translocate a variety of substrates. ABCA6
has been suggested to play an important role in lipid
homeostasis [15]; it was up-regulated in GAN fibroblasts.
ABCB4 is also known as multidrug resistance P-glycopro-
tein 3 and functions as a translocator of phospholipids.
Deficiencies in ABCB4 cause progressive intrahepatic
cholestasis type III [16]. ABCB4 was downregulated in
GAN fibroblasts. In addition, Fatty Acid Binding Protein 5
(FABP5), Meltrin alpha, Complement C3 and Butyrylcho-
linesterase (BChE) were upregulated in GAN fibroblasts.
FABP5 is involved in intracellular fatty-acid trafficking
(reviewed in [17]). Meltrin alpha is a member of the met-
alloprotease-disintegrin family and is involved in adipo-
genesis [18]. C3 is a component of the complement
system of innate immunity. It is also the precursor of an
acylation-stimulating protein that can increase triglycer-
ide synthesis (reviewed in [19]). BChE is a serine hydro-
lase that exhibits increased activity in hyperlipidaemic
patients [20]. Acyl-CoA: Cholesterol Acyltransferase
(ACAT) and Leptin were downregulated in GAN fibrob-
lasts. ACAT is an enzyme that converts intracellular cho-
lesterol into cholesteryl esters and promotes the storage of
excess cholesterol in the form of cholesterol ester droplets
[21]. Leptin is a peptide hormone produced predomi-
nantly by white adipose cells; however, it is also expressed
in non-adipocytes and is important in regulating fatty acid
metabolism (reviewed in [22]).
Cellular studies of lipid droplets in GAN fibroblasts
Because the microarray analysis revealed alterations in the
expression of lipid metabolism genes in GAN fibroblasts,
we studied the distribution of lipid droplets in the fibrob-
last explants by cytological staining. We used Oil Red O
dye to label neutral lipid droplets of serum-starved GAN
and normal fibroblasts. The proportions of cells contain-
ing lipid droplets were significantly higher in the mutant
explants (52% in WG0321, 21% in WG0791) compared
with the normal explants (6% in MCH068, 9% in
MCH070; Fig 4A). In addition, GAN fibroblasts contained
many more droplets per cell than did normal fibroblasts
(Fig. 4B–D). These results were confirmed by Bodipy
staining (data not shown).
Previously, it has been shown that vimentin can form
cage-like structures around lipid droplets in adipocytes.
We wondered whether the vimentin aggregates also sur-
rounded the lipid droplets in GAN cells. We performed
fluorescence microscopy on GAN cells co-stained for
vimentin and lipid droplets. As shown in Fig. 4F–G, while
some of the small vimentin aggregates appeared to encage
lipid droplets, most of them did not (~80% in both cell
lines).
Discussion
In this study, we describe two GAN fibroblast explants
and identify the underlying mutations in the GAN gene.
WG0791 cells contained two different GAN mutant alle-
les, an intronic mutation near the splice donor site of
intron 2 and a missense mutation in exon 3 (I182N).
WG0321 cells carried two identical deletion alleles pre-
dicted to produce a truncated gigaxonin protein. As
revealed by immunocytochemical analysis, both WG0791
and WG0321 cells displayed abnormal vimentin filament
aggregation, a phenomenon exacerbated drastically by
low-serum treatment. By comparing the expression pro-
files of these GAN fibroblasts to two normal fibroblasts
under low-serum conditions, we found that the GAN cells
exhibited defects in lipid metabolism. Unlike normal
fibroblasts, which were virtually devoid of lipid droplets
under these conditions, GAN fibroblasts accumulated a
large number of lipid droplets.
The mechanism that caused lipid defects in GAN fibrob-
lasts is not clear but may involve defects in the vimentin
IFs. GAN has long been considered a disease of IFs, and
earlier studies have shown that vimentin IFs are closely
associated with cytoplasmic lipid droplets in normal cells
(reviewed in [23]). Association of vimentin IFs with lipid
droplets is most obvious in adipose cells where the vimen-
tin network forms a cage-like structure surrounding the
lipid droplets [24]. Similar interactions of vimentin and
lipid droplets have also been observed in steroidogenic
cells [25-27], and the interaction is probably direct asBMC Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2156/8/6
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Table 1: Differentially expressed genes in GAN vs. normal fibroblasts as analyzed by oligonucleotide microarrays. Genes selected 
displayed at least a three-fold difference in expression level.
Name Acc. number Fold change
Genes involved in lipid metabolism and adipogensis
Complement component 3 precursor NM_000064.1 33.67
Butyrylcholinesterase NM_000055 20.67
Alpha-2,8-sialyltransferase L32867.1 6.95
Fatty acid binding protein 5 NM_001444.1 6.48
ATP-binding cassette A6 AA099357 4.38
Meltrin alpha W46291 5.51
Adipsin NM_001928.1 -7.39
ATP-binding cassette B4 NM_000443.2 -9.77
Acyl coenzyme A:cholesterol acyltransferase S73751.1 -24.91
Leptin NM_000230.1 -34.35
Integral membrane proteins and receptors
GABA-B receptor AF056085.1 8.85
Integrin, beta 3 M35999.1 4.89
GABA-B receptor R2 AF095784.1 5.05
GABA-B receptor splice variant 1 AF095723.1 6.06
Orphan G protein-coupled receptor AF069755.1 4.52
Integral membrane serine protease U76833.1 4.63
Hyaluronan-mediated motility receptor NM_012485.1 3.14
Death receptor 6 BE568134 -4.14
Endothelin receptor M74921.1 -5.12
P-glycoprotein (mdr1) AF016535.1 -7.95
Membrane glycoprotein M6 D49958.1 -5.82
C18ORF1 NM_004338.1 -4.19
Glycoprotein M6A BF939489 -6.68
Potassium channel beta subunit L39833.1 -5.44
Endothelin receptor type B NM_003991.1 -8.89
Potassium channel beta 1a subunit U33428.1 -3.99
E-cadherin NM_004360.1 -7.04
Cell division/proliferation/apoptosis
Survivin NM_001168.1 6.37
PDZ-binding kinase NM_018492.1 4.38
Survivin-beta AB028869.1 6.53
Mitosin (CENPF) NM_005196.1 3.79
Dickkopf homolog 1 NM_012242.1 4.59
Kinetochore associated 2 NM_006101.1 3.51
Cell division cycle 2 AL524035 3.47
WNT4 NM_030761.1 -4.05
Fritz U91903.1 -4.83
Tumor necrosis factor-related protein NM_030945.1 -6.03
EGF-like-domain, multiple 6 NM_015507.2 -8.22
Transcription factors and nuclear proteins
Transcription factor AP-2 alpha BF343007 7.41
High mobility group AT-hook 1 NM_002131.1 5.58
Nuclear factor IB AI700518 4.49
Interferon-inducible protein p78 NM_002462.2 7.57
Cytoskeleton
Rabkinesin6 NM_005733.1 4.66
Stathmin-like 2 NM_007029.1 -5.32
Pregnancy specific beta-1-glycoprotein
Pregnancy specific beta-1-glycoprotein 7 NM_002783.1 -5.85
Pregnancy specific beta-1-glycoprotein 4 NM_002780.1 -17.82
Pregnancy specific beta-1-glycoprotein 1 NM_006905.1 -62.90BMC Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2156/8/6
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indicated by in vitro experiments [28,29]. Although the
significance of the vimentin-lipid interactions to cellular
functions has not been clearly defined, there is evidence to
suggest that vimentin IFs play an important role in choles-
terol transport. Using human adrenal carcinoma cells
with or without vimentin IFs, Sarria et al. showed that
there is a direct correlation between the presence of
vimentin IFs and the capacity of the cells to utilize lyso-
somal cholesterol (Sarria et al., 1992). Their studies also
indicated that the intracellular movement of low-density-
lipoprotein (LDL)-derived cholesterol from the lysosomes
to the site of esterification is dependent on vimentin.
Using 3T3-L1 preadipocytes as a model of adipogenesis,
vimentin IFs have been shown to be important for lipid
droplet accumulation during adipose development [30].
Perturbation of the vimentin network in 3T3-L1 cells dur-
ing adipose conversion by nocodazole treatment, anti-IF
antibody microinjection, or over-expression of a domi-
nant-negative vimentin mutant protein could abolish the
formation of lipid storage droplets in the differentiated
adipocytes. The impairment appeared to be the result of
an increased turnover rate of triglyceride synthesis. How-
ever, the significance of vimentin in adipogenesis has
been questioned by the studies of vimentin knockout
mice. Vimentin-null mice were viable and exhibited no
obvious abnormality in adipose development [31].
Importantly, there was no compensatory increase in the
expression of another IF protein. Only some minor
pathologies were observed in the null mice. Specifically,
Uncharacterized genes
Hypothetical protein PRO02730 AL137654 10.56
Uncharacterized bone marrow protein NM_018454.1 5.06
Hypothetical protein FLJ10517 NM_018123.1 5.74
KIAA0101 gene product NM_014736.1 5.10
KIAA0008 gene product NM_014750.1 4.62
Doublecortin and CaM kinase-like 1 NM_004734.1 4.53
KIAA1547 gene product AW873621 3.96
Hypothetical protein DKFZp762E1312 NM_018410.1 4.54
Hypothetical protein FLJ10829 NM_018234.1 5.12
Clone HQ0310 PRO0310p1 NM_016359.1 4.38
Hypothetical protein DKFZp564H1916 AI186739 3.69
KIAA0042 gene product NM_014875.1 4.96
Hypothetical protein FLJ22009 NM_024745.1 4.11
Hypothetical protein FLJ23468 NM_024629.1 3.48
Hypothetical protein DKFZp564N1116 BF344237 4.03
Hypothetical protein FLJ10781 NM_018215.1 -3.68
Myomegalin AB042557.1 -4.97
Hypothetical protein DKFZp564B052 NM_030820.1 -5.46
KIAA0008 gene product AK002054.1 -16.44
MGC:3052 BC002449.1 -7.73
KIAA0865 gene product AI522028 -7.70
Miscellaneous
Matrix metalloproteinase 1 NM_002421.2 7.73
Carbonic anhydrase XII NM_001218.2 7.80
Topoisomerase II alpha AU159942 6.87
Step II splicing factor SLU7 AV733266 6.93
Monocyte chemotactic protein S69738.1 4.37
Ribonucleotide reductase M2 BE966236 4.59
Plasminogen activator, urokinase NM_002658.1 4.19
Cathepsin C NM_001814.1 4.34
Atrophin-1 interacting protein 1 NM_012301.1 -3.89
Monoamine oxidase A AA923354 -4.77
Type II iodothyronine deiodinase U53506.1 -2.80
Phosphatidylserine-binding protein NM_004657.1 -3.98
Scrapie responsive protein 1 NM_007281.1 -5.72
Natural killer cell transcript 4 NM_004221.1 -5.94
CD24 signal transducer L33930 -9.16
Elastase 2 NM_001972.1 -9.71
CD24 antigen AA761181 -19.19
Table 1: Differentially expressed genes in GAN vs. normal fibroblasts as analyzed by oligonucleotide microarrays. Genes selected 
displayed at least a three-fold difference in expression level. (Continued)BMC Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2156/8/6
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Quantitative RT-PCR analyses of the GAN and lipid-metabolism-related genes in fibroblast explants grown in low-serum condi- tions Figure 3
Quantitative RT-PCR analyses of the GAN and lipid-metabolism-related genes in fibroblast explants grown in low-serum condi-
tions. The expression of each gene in MCH070, WG0791 and WG0321 cells was compared to that in MCH068 cells. Each data 
point is the mean of three separate runs. GAPDH was used for normalization.
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Cytological staining of normal and GAN fibroblasts grown under low-serum conditions Figure 4
Cytological staining of normal and GAN fibroblasts grown under low-serum conditions. (A) Percentage of cells containing Red-
Oil-O-positive droplets. (B-D) Fibroblasts MCH070 (B), WG0791 (C) and WG0321 (D) were stained with Oil Red O and 
Hematoxylin dyes. Lipid droplets were stained in red and nuclei were stained in blue. Lipid droplets accumulated in WG0791 
and WG0321 cells but not in MCH070 cells. (E-G) Fibroblasts MCH070 (E), WG0791 (F) and WG0321 (G) were immunos-
tained with monoclonal anti-vimentin V9 antibody and Oil Red O. Vimentin filaments were stained in green and lipid droplets 
were stained in red. Scale bars, 10 μm.
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the glial fibrillary acidic protein network was disrupted in
a subset of astrocytes [32], and the Bergmann fibers of the
cerebellar cortex were hypertrophic [33]. Nonetheless,
cultured embryonic fibroblasts from vimentin-null mice
displayed a significant decrease in the synthesis of gly-
cosphingolipids [34]. The defect appeared to result from
impaired intracellular transport of glycolipids and sphin-
goid bases between the endosomal/lysosomal pathway
and the Golgi apparatus and the endoplasmic reticulum.
It is therefore possible that, in GAN fibroblasts, mutations
of the GAN  gene affect the properties of vimentin IFs,
leading to perturbation of lipid metabolism and accumu-
lation of lipid droplets. Our observation that some low-
serum-treated GAN cells contained vimentin aggregates
but no lipid droplets may be explained by an insufficient
sensitivity of Oil Red O staining. Alternatively, the cells
could still have been in the process of accumulating oil
droplets.
How do GAN mutations lead to defects in IF networks?
One possible mechanism is through the disruption of
MTs, because gigaxonin can affect the degradation of
MAP1B, MAP8 and TBCB [11,12,14]. IFs are closely asso-
ciated with MTs. Disruption of the MT network by noco-
dazole can cause IFs to collapse into the perinuclear
region, and this MT-mediated effect of IFs is more obvious
in GAN fibroblasts than in normal fibroblasts [5]. GAN
mutations may therefore affect MTs, leading to IF aggrega-
tion and ultimately retention of lipid droplets. However,
MT disruption with nocodazole did not have an obvious
effect on the number of lipid droplets in either mutant or
normal fibroblasts (data not shown). These data suggest
that IF aggregation may not be linked mechanistically to
lipid droplet accumulation in GAN cells, but rather that
the observed defects of lipid metabolism in GAN cells are
a compound effect of IF/MT perturbation and other gigax-
onin-related functions.
Conclusion
Here we describe three novel mutant GAN alleles, includ-
ing a missense mutation, an intronic mutation, and a 9.3-
kb deletion. We also characterize two GAN fibroblast
explants and detect perturbations of lipid metabolism in
both of them. Based on the previous studies of vimentin
IFs and lipid metabolism, we speculate that the abnormal
accumulation of lipid droplets that we observe in GAN
fibroblasts is an indirect effect of the GAN mutations and
is probably mediated through IF network disruption.
These fibroblast explants will be a useful tool to study the
physiological functions of gigaxonin.
Methods
Genotyping of fibroblasts
Total RNA was isolated from fibroblasts using Trizol rea-
gent (Invitrogen). First-strand cDNA was synthesized with
oligo-dT primers and reverse transcriptase (Invitrogen).
The procedures were performed according to the manu-
facturer's protocol. Gigaxonin cDNAs were amplified
from the cDNA pool using forward primer, 5'-TTGAT-
GGCTGAGGGCAGTGCCGTGTCTG-3' and reverse
primer, 5'-TTCCTCCTCAAGGGGAATGAACACGAAT-3'.
After electrophoresis, PCR products were purified by the
GeneClean purification system (Q-Biogen) and were
sequenced with the BigDye™ sequencing kit (Applied Bio-
systems). The shorter gigaxonin cDNA products from
explant WG0791 were first cloned into pCR2.1-TOPO
vector (Invitrogen) before sequencing. The conditions
used for genomic PCR and the sequences of the PCR prim-
ers have been reported elsewhere [10].
Cell culture, immunocytochemistry and Oil-Red O staining
Fibroblast explants were obtained from the repository for
mutant human cell strains at McGill University. They were
maintained at 37°C and 5% CO2 in MEM Eagle medium
(Earle's) with 10% fetal bovine serum. For low-serum
treatment, cells were incubated in medium containing
0.1% fetal bovine serum for 72 hours. All experiments
were performed on cells from passages 13–18. For immu-
nocytochemical analyses, cells seeded on coverslips were
fixed with 4% paraformaldehyde for 20 minutes and per-
meabilized with 0.1% Triton-X100 for 5 minutes. Fixed
cells were incubated with primary antibodies at room
temperature for one hour, followed by several washes
with PBS and incubation with appropriate secondary anti-
bodies for 30 minutes. The coverslips were then washed
with PBS and mounted onto slides with Aquamount
(Lerner Laboratories) for immunofluorescent micros-
copy. To co-stain lipid droplets and vimentin filaments,
formaldehyde-fixed cells were permeabilized with 0.05%
Saponin and incubated with an anti-vimentin antibody
overnight. Before mounting onto slides, cells were stained
for lipid droplets with 0.5% Oil Red O in propylene glycol
(Poly Scientific). To stain the nuclei and the lipid droplets,
cells were fixed in 4% paraformaldehyde and incubated
with 0.5% Oil Red O in propylene glycol and Gill's Hema-
toxylin I (Poly Scientific) for 20 minutes. Antibodies used:
monoclonal mouse anti-vimentin, clone V9 (Sigma),
monoclonal mouse pan anti-keratin (Sigma), and poly-
clonal anti-vimentin [35].
Microarray analysis
Human 133A Genechips from Affymetrix were used to
study the expression profiles. Biotin-labeled cRNA probes
were prepared according to the manufacturer's protocol.
In brief, cells were treated with low-serum medium for 72
hours, and total RNA was extracted. First-strand cDNAs
were synthesized with oligo-dT-T7 primers and reverse
transcriptase (Invitrogen). After second-strand cDNA syn-
thesis, double-stranded cDNAs were used to produce
biotin-labeled cRNA probes by T7 polymerase (Enzo Lab-BMC Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2156/8/6
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oratory). The cRNAs were fragmented before being used
for hybridization. Hybridization and scanning were car-
ried out at the GeneChip analysis facility at Columbia
University.
GeneChip results were analyzed by Affymetrix Microarray
Suite (version 5.0). To reduce background noise, a four-
way comparison of MCH068, MCH070, WG0321 and
WG0791 cells was performed. Only genes that showed
consistent changes in both WG0321 and WG0791 fibrob-
lasts when compared to both MCH068 and MCH070 cells
were selected. Genes that exhibited more than three-fold
differences were considered as significantly altered.
Quantitative PCR
To determine the relative expression levels of a gene,
quantitative PCR was performed on cDNAs prepared from
normal and GAN fibroblasts. Single-stranded cDNAs were
generated from total RNA with Oligo-dT primers and
reverse transcriptase (Invitrogen). Quantitative PCR was
performed on a SmartCycler II PCR machine (Cephid)
with gene-specific primers, SyBr Green fluorescence dye,
and OmniMix HS PCR master mix (TakaRa). The
sequences of the PCR primers and the PCR conditions are
shown in Table 2. GAPDH was used as the internal con-
trol, and the fold difference of a gene-of-interest in
MCH070, WG0321 and WG0791 relative to MCH068
was calculated using the ΔΔCt method [36].
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